← Back to Search

Dietary Supplement

Niagen for Post-COVID Syndrome

Phase 4
Waitlist Available
Led By Edmarie Guzman-Velez, PhD
Research Sponsored by Massachusetts General Hospital
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up baseline, 12 and 22 weeks
Awards & highlights

Study Summary

This trial will study whether Niagen can help improve symptoms in people who have had COVID-19 for at least 2 months. 60% will take Niagen and 40% will take a placebo. Outcomes will be based on standard cognitive, neuropsychiatric, physical, functional, and biomarker assessments.

Who is the study for?
This trial is for individuals who have had COVID-19 and are experiencing ongoing neurological or physical symptoms like fatigue, headaches, or 'brain fog' at least two months after infection. Participants must not be pregnant, lactating, or have a history of hypersensitivity to nicotinamide riboside. They should not be using psychoactive medications that affect cognition and must not have any major psychiatric illness within the last year.Check my eligibility
What is being tested?
The study tests Niagen, a dietary supplement, to see if it helps people with Long-COVID recover from persistent cognitive and physical symptoms. Sixty percent of participants will receive Niagen while forty percent will get a placebo (PBO). The effects will be measured through various assessments including cognitive tests and biomarkers.See study design
What are the potential side effects?
While the description does not list specific side effects for Niagen in this context, as a dietary supplement it may cause mild issues such as nausea or indigestion. However, since it's being tested in Long-COVID patients here, monitoring for unexpected reactions is part of the trial.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~baseline, 12 and 22 weeks
This trial's timeline: 3 weeks for screening, Varies for treatment, and baseline, 12 and 22 weeks for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Cognition
Secondary outcome measures
Examine the effect of Niagen in COVID-related physical symptoms
Examine the effect of Niagen in anxiety symptoms
Examine the effect of Niagen in depression symptoms

Side effects data

From 2009 Phase 3 trial • 44 Patients • NCT00116207
82%
Non-Serious Adverse Events
5%
Suicide Attempt
100%
80%
60%
40%
20%
0%
Study treatment Arm
Placebo
ORAL ANTIOXIDANT

Trial Design

2Treatment groups
Experimental Treatment
Placebo Group
Group I: NiagenExperimental Treatment1 Intervention
Supplement: 60 participants will take Niagen 2000mg in the form of capsules daily.
Group II: PlaceboPlacebo Group1 Intervention
Placebo: 40 participants will take placebo in the form of a capsule.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Nicotinamide riboside
Not yet FDA approved

Find a Location

Who is running the clinical trial?

Massachusetts General HospitalLead Sponsor
2,928 Previous Clinical Trials
13,198,285 Total Patients Enrolled
Edmarie Guzman-Velez, PhDPrincipal Investigator - Massachusetts General Hospital and Harvard Medical School
Massachusetts General Hospital

Media Library

Niagen (Dietary Supplement) Clinical Trial Eligibility Overview. Trial Name: NCT04809974 — Phase 4
Cognitive Symptoms Research Study Groups: Niagen, Placebo
Cognitive Symptoms Clinical Trial 2023: Niagen Highlights & Side Effects. Trial Name: NCT04809974 — Phase 4
Niagen (Dietary Supplement) 2023 Treatment Timeline for Medical Study. Trial Name: NCT04809974 — Phase 4

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

What other scientific research has been conducted on Niagen?

"At present time, there are 16 ongoing clinical trials studying Niagen with 1 trial in Phase 3. While the majority of the clinical trials for Niagen are based in Iowa City, Iowa, there are 20 locations operating clinical trials for Niagen."

Answered by AI

Are researchers still signing up participants for this trial?

"The trial is currently searching for 100 participants across 1 locations, as indicated by the data on clinicaltrials.gov. The trial was originally posted on 7/22/2021 and was most recently edited on 8/23/2022."

Answered by AI

Are there age restrictions for participants in this experiment?

"Eligibility requirements for this particular trial include being between 18-65 years old. Out of the 2454 total clinical trials, 146 are geared towards minors and 1008 are for adults over 65."

Answered by AI

Could you tell me how many individuals are involved in this test?

"Yes, the information on clinicaltrials.gov indicates that this study is currently searching for candidates. The study was first posted on 7/22/2021 and was last updated on 8/23/2022. The study is recruiting for 100 patients between 1 sites."

Answered by AI

Is there a high potential for harm when taking Niagen?

"Since this is a Phase 4 trial, meaning the treatment has been approved, we estimate the safety of Niagen to be a 3."

Answered by AI
Recent research and studies
clinicaltrials.govStudy
Clinical Trial of Niagen to Examine Recovery in People With Persistent Cognitive and Physical Symptoms After COVID-19 Illness (Long-COVID)
Edmarie Guzman-Velez 2021. "Clinical Trial of Niagen to Examine Recovery in People With Persistent Cognitive and Physical Symptoms After COVID-19 Illness (Long-COVID)". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT04809974.
~19 spots leftby Apr 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top